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http://www.biomedcentral.com/1471-2407/12/365RESEARCH ARTICLE Open AccessElevated levels of serum amyloid A indicate poor
prognosis in patients with esophageal squamous
cell carcinoma
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Background: Increase of Serum amyloid A (SAA) level has been observed in patients with a variety of cancers. The
objective of this study was to determined whether SAA level could be used as a prognostic parameter in patients
with esophageal squamous cell carcinoma (ESCC).
Methods: SAA levels were measured by rate nephelometry immunoassay in 167 healthy controls and 167 ESCC
patients prior to surgical resection. Statistical associations between clinicopathological observations and SAA levels
were determined using the Mann–Whitney U test. The clinical value of SAA level as a prognostic parameter was
evaluated using the Cox’s proportional hazards model.
Results: SAA levels were significantly higher in patients with ESCC compared to levels in healthy controls
(13.88 ± 15.19 mg/L vs. 2.26 ± 1.66 mg/L, P< 0.001). Elevation of SAA levels (≥ 8.0 mg/L) was observed in 54.5%
(91/167) of patients with ESCC but not in healthy controls. SAA levels were associated with tumor size (P< 0.001),
histological differentiation (P= 0.015), T classification (P< 0.001), clinical stage (P< 0.001), lymph node metastasis
(P< 0.001) and distant metastasis (P< 0.001), but not with the age and gender of the patients or tumor location.
Multivariate analysis revealed that patients with an elevated level of SAA (≥ 8.0 mg/L) had significantly lower 5-year
survival rate than those with non-elevated SAA (< 8.0 mg/L, log-rank P< 0.0001).
Conclusions: An elevated level of preoperative SAA was found to associate with tumor progression and poor
survival in patients with ESCC.
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Chronic inflammation has been recognized as a key fac-
tor that contributes to the development and progression
of a wide range of malignancies [1]. A number of studies
suggest that inflammatory status is a prognostic factor
for many cancers [2-4]. Serum amyloid A (SAA), an
acute phase reactant, is a high-density lipoprotein-
associated lipoprotein. It is well-known as a modulator
of inflammation and it plays a major role in the* Correspondence: zhangge@mail.sysu.edu.cn; liuwl@sysucc.org.cn
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reproduction in any medium, provided the ormetabolism and transport of cholesterol [5]. Levels of
SAA may rapidly increase by up to 1000-fold in response
to acute inflammation, and it is a well-established indi-
cator of inflammation in the body [6]. SAA is also used
to assess low-grade chronic inflammation.
SAA has been investigated in various human malig-
nancies as a predictor of cancer risk and as a prognostic
parameter [7-9]. Interestingly, SAA has been recently
identified by serum proteomic technologies as a poten-
tially useful biomarker for human tumors, including
renal cell carcinoma [10], lung cancer [11], melanoma
[12], endometrial cancer [13] and nasopharyngeal cancer
[14]. Elevated levels of SAA have been used as a non-
invasive biomarker for prognosis of many cancers, such
as breast cancer [15], lung cancer [16], melanoma [12],
gastric cancer [17] and endometrial cancer [13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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squamous cell carcinoma (ESCC) that used mass spec-
trometry and proteomic technologies found that SAA
was upregulated and could be used to differentiate
patients from healthy individuals [18]. ESCC, the major
histopathological form of esophageal cancer, is one of
the most lethal malignancies of the digestive tract and is
the fourth most frequent cause of cancer deaths in
China [19]. Inflammatory status has been reported to be
a prognostic factor for ESCC. Elevated concentrations of
serum C-reactive protein (CRP), another commonly
used marker of inflammation, have been shown to be
associated with disease progression and poor prognosis
in patients with ESCC [20-22]. However, the relationship
between SAA and ESCC progression is still unclear.
In this study, we measured the preoperative SAA levels
in 167 patients with ESCC to evaluate the clinical value
of SAA as a prognostic parameter in those patients.
Methods
Patients and sera
In this study, patients with elevated white blood cell
count (>10 × 109/L) were considered with inflammatory
diseases and were excluded before the measurement of
SAA. At last, 167 patients with primary ESCC treated
between January 2005 and January 2007 in the Cancer
Center of Sun Yat-Sen University were enrolled and con-
sidered as the case group. In the cohort, 129 patients
were male and 38 patients were female. There were 2
cases with atherosclerotic disease and 6 cases with
COPD in group with serum SAA levels≧8.0 mg/L; there
were 3 cases with atherosclerotic disease and 4 cases
with COPD in group with serum SAA levels < 8.0 mg/L.
The patients ranged in age from 38 to 81 years (mean,
58.5 years); none had received radiotherapy or chemo-
therapy prior to surgery. The patient characteristics are
described in Table 1. Surgical resection in this cohort of
patients consisted of transthoracic en bloc esophagect-
omy with two- or three-field lymphadenectomy. All of
the patients were classified according to the TNM classi-
fication system and resected specimens underwent
pathological examination [23]. A total of 123 patients
with ESCC underwent surgical resection only, 44
patients received additional platinum-based adjuvant
chemotherapy and/or radiotherapy at the discretion of
the surgeon and/or oncologist.
Overall survival (OS) was defined as the interval be-
tween the date of surgery and the date of death or the date
of the last known follow-up visit. Two patients died of
causes unrelated to ESCC. The follow-up data from the
ESCC patients in this study were available and complete.
Sera from 167 healthy volunteers (129 males, 38
females) with ages ranging from 40 to 70 years (mean:
57.8 years) were collected in physical examination, therewere 1 case with atherosclerotic disease and 2 cases with
COPD. Healthy controls were selected from an archive
of blood samples; the control samples were matched as
closely as possible to the ESCC group for sex, previous
handling and the time period of sample collection.
A 5-ml blood sample from each participant (ESCC
patients and health controls) was allowed to clot for 30
to 60 min at room temperature. Each clotted samples
was centrifuged at 1,500 g for 10 min. All sera were ali-
quoted and frozen at −70°C until use. This study was
approved by the Institute Research Ethics Committee of
the Cancer Center of Sun Yat-Sen University and
informed consents were obtained from all participants
before theirs sera were used.
Immunoassay of SAA
The concentration of SAA was determined in both the
ESCC sera and the healthy control sera using rate
nephelometry performed on a BN ProSpec System (Sie-
mens, Germany) with an SAA assay kit based on a poly-
clonal antibody (Siemens Healthcare Diagnostics
Products GmbH, Germany). The normal level for SAA
in the healthy Chinese population is < 8.0 mg/L accord-
ing to the kit's protocol.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package (SPSS Inc., Chicago, IL).
The Mann–Whitney U test was used to evaluate the dif-
ference in SAA concentrations between ESCC patients
and healthy controls and to analyze the association be-
tween SAA levels and the observed clinicopathological
characteristics of patients with ESCC. Pearson's chi-
squared test was used to analyze the relationship be-
tween SAA levels and gender. Survival curves were plot-
ted by the Kaplan-Meier method and compared using
the log rank test. The significance of various variables
for survival was analyzed using the Cox proportional
hazards model (univariate and multivariate analysis).
P < 0.05 was considered to be statistically significant in
all cases.
Results
Figure 1 shows the level of SAA in the healthy controls
(n = 167) and ESCC patients (n = 167), respectively. The
mean SAA levels in the healthy controls and ESCC
patients prior to surgery were 2.26 mg/L (SD, 1.66;
range, 0.10-6.50) and 13.88 mg/L (SD, 15.19; range,
0.76-76.1), respectively. SAA values from ESCC patients
were significantly higher than those from the healthy
controls (P < 0.001).
Extremely high levels of SAA were found only in the
patient group. The maximum concentration of SAA that
was regarded as normal was set at 8.0 mg/L, as specified
Table 1 Relationship between the SAA concentration and the clinicopathological variables in 167 patients with
esophageal carcinoma
Variables Cases SAA(mg/L) Significance SAA SAA Significance
(n) (Mean±SD) (P)* <8.0 mg/L ≥8.0 mg/L (P)*
Gender
Male 129 14.89±15.72 0.084 54 75 0.126
Female 38 10.62±13.01 21 17
Age (y)
<60 83 12.57±13.58 0.083 43 40 0.086
≥60 84 15.41±16.74 32 52
Location
Up 49 15.32±17.36 0.381 23 26 0.361
Middle 88 12.61±14.51 43 45
Low 30 15.80±13.81 10 20
Tumor diameter
<50 mm 102 8.02±9.30 <0.001 66 36 <0.001
≥50 mm 65 23.15±17.93 10 55
Histological differentiation
Well 53 5.91±3.59 0.015 35 18 <0.001
Moderate 73 16.76±8.88 27 46
Poor 21 17.42±17.22 4 17
pT classification
T1 11 5.06±4.79 <0.001 7 4 <0.001
T2 23 7.17±6.81 16 7
T3 93 12.96±13.59 42 51
T4 40 22.08±20.02 6 34
pN classification
No 72 9.99±12.88 0.006 43 29 <0.001
Yes 95 17.03±16.38 29 66
pMetastasis
No 132 10.21±10.97 <0.001 68 64 <0.001
Yes 35 27.92±20.42 4 31
Stage
I 17 5.82±4.81 <0.001 13 4 <0.001
IIa 25 6.90±13.76 16 9
IIb 25 8.82±7.88 15 10
III 61 11.68±9.60 26 35
IV 39 27.73±20.58 3 36
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above this value (≥ 8.0 mg/L) were observed in 54.5%
(91/167) of patients with ESCC, however, none of the
167 healthy controls had serum SAA levels above
8.0 mg/L.
The associations between median serum SAA levels
and clinicopathological parameters are presented in
Table 1. SAA levels were not associated with age, gender
and tumor location; however, elevated meadian SAA
levels were significant for patients with larger tumors (≥50 mm; P < 0.001) and for those with more advanced
disease, including lymph node metastasis (P= 0.006) and
distant metastasis (P < 0.001). There was also an associ-
ation between raised SAA levels and poorly differen-
tiated tumors (P= 0.015). We also noted that the median
levels of SAA significantly increased with increasing T
classification (P < 0.001) and clinical stage (P < 0.001) of
the malignancy.
Next, patients were classified into two groups accord-
ing to their SAA level (< 8.0 mg/L vs. ≥ 8.0 mg/L); the
Figure 1 Scatter plots of preoperative serum SAA levels in
patients with ESCC (n = 167) and in healthy controls (n = 167).
There was a significant difference between these two groups
(P< 0.001). Abnormally high levels of SAA were found only in the
patient group.
Figure 2 Comparison of overall survival between different
stages.
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parameters were assessed. No significant difference in
age, gender and tumor location was found between the
two groups; however, patients with poor histological dif-
ferentiation (P < 0.001), larger tumor size (P < 0.001),
higher T classification (P < 0.001), lymph node metastasis
(P < 0.001), distant metastasis (P < 0.001) and higher clin-
ical stage (P < 0.001) were more frequently observed in
the elevated SAA group (SAA ≥ 8.0 mg/L) than in the
non-elevated SAA group (SAA< 8.0 mg/L).
The overall survival of patients with ESCC was plotted
using the Kaplan-Meier method and a log-rank test was
employed to evaluate the prognostic significance of SAA
levels. Of the entire cohort, the predicted five-year over-
all survival rate was 41%, with a median survival time of
45.0 months (range from 1 month to 78 months).
Figure 2 shows the comparison of survival time between
different stages.
The group with non-elevated SAA levels (< 8.0 mg/L)
showed a significantly better 5-year survival rate than
the elevated SAA group (≥ 8.0 mg/L; Figure 3a). The cu-
mulative 5-year survival rate in the non-elevated SAA
group was 64.1%, whereas it was only 13.2% in the ele-
vated SAA group (log-rank P < 0.0001).
We also analyzed the prognostic value of SAA levels
in selective patient subgroups stratified according to the
disease stage, and T and N classifications, respectively.
ESCC patients with elevated SAA levels had significantly
shorter overall survival rate compared to patients with
non-elevated SAA levels in the clinical stage I-II sub-
group (n = 64; log-rank P < 0.0001; Figure 3b), the clinical
stage III-IV subgroup (n = 101; log-rank P < 0.0001;
Figure 3c), the T1-T2 subgroup (n = 34; log rankP= 0.016; Figure 3d), the T3-T4 subgroup (n = 131; log
rank, P < 0.0001; Figure 3e), the N0 subgroup (n = 72; log
rank, P < 0.0001; Figure 3f ) and the N1 subgroup (n = 93;
log-rank, P < 0.0001; Figure 3g).
Results of univariate Kaplan-Meier analysis and the
multivariate Cox regression model with respect to over-
all survival rate are shown in Table 2. Clinical stage, N
classification and SAA levels are significantly correlated
with survival in univariate Kaplan-Meier analysis (log
rank test P < 0.001) respectively. To determine whether
SAA levels could be used as an independent prognostic
factor for outcomes we performed a multivariate analysis
for survival, based on SAA levels, age, clinical stage, N
classification and gender. In this analysis, clinical stage
(log rank test P= 0.047), N classification (log rank test
P < 0.001) and SAA levels (log rank test P < 0.001) were
recognized as independent prognostic factors (Table 2).
Thus, our findings indicate that the preoperative serum
SAA level is an independent prognostic factor for
esophageal squamous cell carcinoma.Discussion
Inflammation appears to play an important role in esopha-
geal carcinogenesis [24]. Mechanisms of inflammation-
associated tumor development have been well studied
Figure 3 Overall survival curves for patients with ESCC after curative resection. The patients were categorized with elevated (≥ 8.0 mg/L)
or non-elevated (< 8.0 mg/L) levels of SAA. The P-values were determined using the log rank test. all patients (a); clinical stage I-II subgroup (b);
clinical stage III-IV subgroup (c); T1-T2 subgroup (d); T3-T4 subgroup (e); N0 subgroup (f); N1 subgroup (g).
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cytokines and inflammatory enzymes.
SAA, a well-established indicator of inflammation, is a
nonspecific, acute-phase, hepatic protein secreted in re-
sponse to cytokines such as interleukin-1, interleukin-6and tumor necrosis factor α [26]. SAA participates in
cholesterol transport, extracellular matrix degradation
and the recruitment of inflammatory cells [5]. Accumu-
lating evidence has suggested that SAA might be used in
the clinic to detect a pattern of physiological events that
Table 2 Univariate and multivariate survival analysis in patients with esophageal carcinoma
Characteristic Univariate analysis Multivariate analysis
HR 95% CI P value* HR 95% CI P value*
Age, years
< 60 vs. ≥60 1.242 0.847-1.823 0.267 1.254 0.835-1.789 0.302
Gender
Male vs. Female 0.822 0.510-1.327 0.423 0.568 0.316-0.863 0.093
pN metastasis
Yes vs. No 1.923 1.112-2.545 <0.001 1.897 1.237-2.675 0.001
pTNM stage
I-II vs. III-IV 3.3500 2.112-5.315 <0.001 1.636 1.005-2.661 0.047
SAA level
<8.0 mg/L vs. 12.217 7.162-20.842 <0.001 6.762 2.941-15.548 <0.001
≥8.0 mg/L
Abbreviations: HR, Hazard ratio; 95% CI, 95% confidence interval; * Cox hazard regression modal.
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response [7]. Elevated SAA levels have been observed in
patients with renal cancer [10], melanoma [12], endo-
metrial cancer [13], nasopharyngeal carcinoma [14], lung
cancer [16], gastric cancer [17], colorectal cancer [27]
and breast cancer [15]. A previous study using mass
spectroscopy found that serum SAA levels increased sig-
nificantly in postoperative ESCC patients compared with
preoperative patients and healthy subjects [18]. However,
this study did not determine whether the elevated levels
of SAA were related to ESCC or the trauma of surgery.
In this study, we first showed that about 6.1-fold higher
levels of SAA in ESCC patients' preoperative sera compared
to healthy controls (13.88 mg/L±15.19 mg/L vs. 2.26 mg/
L±1.66 mg/L). We have demonstrated that the preopera-
tive serum SAA level may be an independent and import-
ant prognostic indicator in patients with ESCC following
curative esophageal resection. The SAA concentration cor-
related significantly with unfavorable clinicopathological
factors such as tumor size, T stage, clinical stage, lymph
node metastasis and distant metastasis.
In present study, we have obtained similar prognosis
compared with previous studies [28,29]. However, the
survival curve was indiscriminate between stage I and II
(P= 0.976), this may be contributed to the small sample
size and, most patients of stage II were nodal negative.
The overall survival rate among patients with elevated
SAA (≥ 8.0 mg/L) was significantly lower compared with
the rate in the group of patients with non-elevated SAA
levels (< 8.0 mg/L). Patients with elevated SAA levels
had shorter survival durations compared to those with
non-elevated SAA levels. The current data are consistent
with previous studies that support the use of SAA as an
independent prognostic marker in renal cancer [10],
melanoma [12] and lung cancer [16].
It has been reported that SAA is produced by the
liver and enters the systemic circulation in responseto stimulation by inflammatory cytokines, such as
interleukin-6 (IL-6). IL-6 is a potent proinflammatory
cytokine and is produced at local tissue sites. It stimu-
lates the liver to produce acute phase proteins, including
SAA [26]. Elevated serum levels of IL-6 have been
shown to be correlated with disease progression and
poor prognosis in patients with esophageal cancer [30].
It has also been observed that IL-6 expression is elevated
(increases in both mRNA and protein concentrations) in
esophageal tumor tissues; serum levels of IL-6 have also
been correlated with tumor volume. In present study,
our data show that gradual elevation of serum SAA
levels are associated with increasing T classification, in-
creasing clinical stage as well as disease progression.
Based upon these results, we speculate that the rise in
SAA may be caused by excess inflammatory cytokines,
in particular IL-6, which has previously been shown to
be produced by the large number of cancer cells in
patients with advanced esophageal carcinoma [31].
On the other hand, elevated SAA levels may also be a
primary product of tumors. Highly expressed SAA has
been observed in lung cancer tissues and in vitro experi-
ments have shown that the SAA protein can be induced
in lung cancer cells by their interaction with THP-1
monocytes [11]. The secretion of SAA by tumor cells
has also been measured in renal cancer [10], endometrial
carcinoma [13], colorectal cancer [27] and ovarian car-
cinoma [32]. However, it remains unknown whether
esophageal tumor cells express SAA; further investiga-
tions are needed to determine whether ESCC tumor
tissue-derived cytokines stimulate SAA synthesis in
esophageal epithelial cells and thus contribute to ele-
vated circulating SAA levels.
The functions of the SAA protein, described in the
context as inflammation, are compatible with the mech-
anism of tumor invasion and metastasis. A previous
study in animal models has demonstrated that the
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(LLC) cells to metastasize and colonize in the lung [11].
It was found that SAA bound to extracellular matrix
components with results of subsequent potential modifi-
cation of cell binding, enhancement of plasminogen acti-
vation, stimulation of matrix metalloproteinase (MMP)
production, and increase of the invasive potential of
tumor cells [33]. It was also reported that SAA stimu-
lated M-CSF and MCP-1 expression in hepatocellular
carcinoma cells; and these factors skewed M1 tumor-
associated macrophages into M2 tumor-associated
macrophages, which exacerbated HCC invasion both
in vitro and in vivo [34]. Additionally, SAA-1 could in-
duce anti-inflammatory interleukin-10 (IL-10)-secreting
neutrophils, which have been linked to the consequent
promotion of melanoma progression [35]. All these
known effects of SAA in tumor invasion and metastasis
may explain our findings that significantly higher con-
centrations of SAA were observed in patients with
lymph node or distant metastatic disease, and patients
with an elevated level of SAA (≥ 8.0 mg/L) had signifi-
cantly lower 5-year survival rate than those with non-
elevated SAA (< 8.0 mg/L).
Conclusion
In conclusion, our study revealed that an elevated level
of preoperative serum SAA was significantly associated
with progressive disease and reduced survival durations
in patients with ESCC. This finding might serve as the
basis to explain the poor progression of patients who
have undergone ESCC resection. The measurement of
SAA is simple, cheap and well-established in clinical
chemistry laboratories. This immunoassay could provide
a relatively inexpensive and objective clinical prognostic
tool for the assessment of ESCC progression.
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